CATX FY2024 EPS Estimate Boosted by Cantor Fitzgerald

Perspective Therapeutics, Inc. (NYSE:CATX) – Stock analysts at Cantor Fitzgerald upped their FY2024 earnings per share estimates for shares of Perspective Therapeutics in a note issued to investors on Wednesday, November 13th. Cantor Fitzgerald analyst L. Chen now expects that the company will post earnings per share of ($0.90) for the year, up from their prior estimate of ($0.95). Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Perspective Therapeutics’ current full-year earnings is ($0.86) per share.

Perspective Therapeutics (NYSE:CATX) last issued its earnings results on Tuesday, November 12th. The company reported ($0.21) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.21). The firm had revenue of $0.37 million for the quarter. Perspective Therapeutics had a negative net margin of 4,096.66% and a negative return on equity of 27.40%.

A number of other equities analysts also recently issued reports on CATX. Wedbush reissued an “outperform” rating and issued a $20.00 price target on shares of Perspective Therapeutics in a research note on Thursday, October 24th. Bank of America began coverage on Perspective Therapeutics in a research report on Thursday, July 25th. They set a “buy” rating and a $24.00 price target on the stock. UBS Group started coverage on Perspective Therapeutics in a research report on Thursday, October 24th. They set a “buy” rating and a $20.00 price objective for the company. Royal Bank of Canada reduced their target price on shares of Perspective Therapeutics from $29.00 to $27.00 and set an “outperform” rating on the stock in a research report on Friday, August 16th. Finally, Oppenheimer reissued an “outperform” rating and set a $22.00 price target on shares of Perspective Therapeutics in a research report on Friday, October 11th. Nine research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Perspective Therapeutics has an average rating of “Buy” and an average price target of $21.57.

Perspective Therapeutics Stock Performance

Shares of CATX stock opened at $7.88 on Monday. Perspective Therapeutics has a fifty-two week low of $2.28 and a fifty-two week high of $19.05. The stock has a 50 day simple moving average of $12.55.

Institutional Trading of Perspective Therapeutics

A number of institutional investors have recently bought and sold shares of CATX. The Manufacturers Life Insurance Company raised its position in Perspective Therapeutics by 8.9% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 20,514 shares of the company’s stock valued at $274,000 after purchasing an additional 1,672 shares in the last quarter. Sykon Capital LLC increased its stake in shares of Perspective Therapeutics by 4.7% during the second quarter. Sykon Capital LLC now owns 37,932 shares of the company’s stock valued at $378,000 after buying an additional 1,717 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of Perspective Therapeutics by 5.8% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 58,678 shares of the company’s stock valued at $783,000 after acquiring an additional 3,211 shares in the last quarter. US Bancorp DE lifted its stake in Perspective Therapeutics by 142.7% in the third quarter. US Bancorp DE now owns 6,576 shares of the company’s stock worth $88,000 after acquiring an additional 3,866 shares during the period. Finally, nVerses Capital LLC bought a new position in Perspective Therapeutics during the 3rd quarter worth about $57,000. 54.66% of the stock is currently owned by institutional investors.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.